Showing results (1821-1830 of 3,640) with videos related to

Sort By:
Pageof 364
Breast (Edinburgh, Scotland)|March 13, 2012
Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patientsFrancesca Galardi, Catherine Oakman, Maria Caterina Truglia, et al.
Breast (Edinburgh, Scotland)|March 20, 2012
1st International consensus guidelines for advanced breast cancer (ABC 1)F Cardoso, A Costa, L Norton, et al.
Breast (Edinburgh, Scotland)|February 1, 2012
Breast cancer early detection methods for low and middle income countries, a review of the evidenceMarilys Corbex, Robert Burton, Hélène Sancho-Garnier
Breast (Edinburgh, Scotland)|September 17, 2008
Patients' decision-making in a UK specialist centre with high mastectomy ratesRachel S Ballinger, Karl Fortes Mayer, Gill Lawrence, et al.
Breast (Edinburgh, Scotland)|September 25, 2007
Breast surgery in advanced breast cancer: local control in the presence of metastasesWilliam C Wood
Breast (Edinburgh, Scotland)|September 25, 2007
Should internal mammary chain (IMC) sentinel node biopsy be performed? Outcome in 90 consecutive non-biopsied patients with a positive IMC scintigraphyM W J M Wouters, A N van Geel, M Menke-Pluijmers, et al.
Breast (Edinburgh, Scotland)|July 4, 2008
Dose variation and regimen modification of adjuvant chemotherapy in daily practice affect survival of stage I-II and operable stage III Taiwanese breast cancer patientsSung-Hsin Kuo, Huang-Chun Lien, San-Lin You, et al.
Breast (Edinburgh, Scotland)|July 26, 2008
The value of a combination of wire localization and ultrasound-guided vacuum-assisted breast biopsy for clustered microcalcificationsKi Seok Choo, Hee Suk Kwak, Young Tae Bae, et al.
Breast (Edinburgh, Scotland)|October 8, 2021
Development of a novel nomogram-based online tool to predict axillary status after neoadjuvant chemotherapy in cN+ breast cancer: A multicentre study on 1,950 patientsFabio Corsi, Sara Albasini, Luca Sorrentino, et al.
Breast (Edinburgh, Scotland)|February 8, 2022
Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trialPaul Cottu, Alistair Ring, Hikmat Abdel-Razeq, et al.
Pageof 364